6/25/2025

Bio-Techne Corporation (NASDAQ:TECH) is one of the best S&P 500 stocks with huge upside potential. On June 24, Bio-Techne Corporation announced a distribution agreement with the US Pharmacopeia/USP. The collaboration allows Bio-Techne to sell USP monoclonal antibody/mAb and recombinant adeno-associated virus/AAV reference standards alongside its analytical solutions, like the Maurice system, to support the global […]

Source: Yahoo

6/25/2025

Bio-Techne has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.

Source: Yahoo

6/24/2025

Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world.

Source: Yahoo

6/24/2025

Bio-Techne Corporation announced a distribution agreement with the U.S. Pharmacopeia that enables the Company to sell USP monoclonal antibody and recombant adeno-associated virus reference...

Source: Finnhub

6/18/2025

Bio-Techne Corp. stock outperforms competitors on strong trading day

Source: MarketWatch

6/17/2025

Bio-Techne Corp. stock underperforms Tuesday when compared to competitors

Source: MarketWatch

6/16/2025

Bio-Techne appears overvalued despite strong revenue growth, solid debt coverage, and looming U.S. healthcare funding cuts. Find out why TECH stock is a hold.

Source: SeekingAlpha

6/13/2025

Bio-Techne Corp. stock underperforms Friday when compared to competitors

Source: MarketWatch

6/10/2025

Life sciences company Bio-Techne (NASDAQ:TECH) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.2% year on year to $316.2 million. Its non-GAAP profit of $0.56 per share was 10.4% above analysts’ consensus estimates.

Source: Yahoo

6/10/2025

Presenter SpeechMatthew Sykes Good morning, everyone. My name is Matt Sykes, the life science tools and diagnostics analyst at Goldman Sachs. And today, I have the pleasure of welcoming Jim Hippel,...

Source: Finnhub

6/10/2025

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.

Source: Yahoo

6/6/2025

Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?

Source: MarketWatch

6/6/2025

Bio-Techne faces significant macro and policy headwinds, including reduced academic research funding, China risks, and U.S. healthcare reforms. Learn more on TECH stock here.

Source: SeekingAlpha

6/5/2025

Source: SeekingAlpha

6/5/2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Source: Yahoo

6/4/2025

Presenter SpeechTycho Peterson Let's get started. I'm Tycho Peterson from the life science team. It's my pleasure to introduce Bio-Techne.QuestionTycho Peterson Maybe just to kick it off and start...

Source: Finnhub

6/4/2025

Purposeful Innovation Leads to Better Answers Kim Kelderman President s CEO June 3, 2025 © 2025 Bio-Techne®....

Source: Finnhub

6/3/2025

Presenter SpeechMatthew Larew Okay. Thanks, everyone, for hanging with us towards the end of the day here. And thanks for joining us for the Bio-Techne management presentation. My name is Matt

Source: Finnhub

6/3/2025

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bio-Techne (NASDAQ:TECH) and the best and worst performers in the research tools & consumables industry.

Source: Yahoo

5/30/2025

The Conservative Allocation Fund's Institutional Class returned -0.24% for the first quarter compared to +1.95% for the Morningstar Moderately Conservative...

Source: SeekingAlpha